Announcements Trials
Browse Landscape

Phase

Phase 1 3

Status

Completed 3

Sponsor Class

INDUSTRY 3OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Breast 32Other solid neoplasm 3Head & Neck 3Gynecologic 3Gastrointestinal 3Endocrine 2Thoracic 1Sarcoma 1Plasma cell 1Genitourinary 1

Conditions

Advanced and Selected Solid Tumors 1Advanced Solid Tumors With an Alteration of the PIK3CA Gene 1Advanced Solid Tumor 1

Interventions

Injections 98pembrolizumab 90Carboplatin 57Paclitaxel 54Cisplatin 52Nivolumab 44Docetaxel 43Pemetrexed 42Gemcitabine 37atezolizumab 32tislelizumab 29Bevacizumab 29toripalimab 23Fluorouracil 23Capecitabine 23Irinotecan 22Oxaliplatin 20durvalumab 19Ipilimumab 18Leucovorin 17Cetuximab 17Rifampin 14Itraconazole 14olaparib 13spartalizumab 12Midazolam 12Cyclophosphamide 12trifluridine tipiracil drug combination 11sintilimab 11Drug Therapy 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
INDUSTRY × Alpelisib × Other solid neoplasm × Clear all
NCT01387321 2020-12-08

A Study of BYL719 in Adult Patients With Advanced Solid Malignancies

Novartis

Phase 1 Completed
33 enrolled
Other solid neoplasm

Advanced Solid Tumor

NCT01219699 2020-09-22

A Study of BYL719 in Adult Patients With Advanced Solid Malignancies, Whose Tumors Have an Alteration of the PIK3CA Gene

Novartis

Phase 1 Completed
221 enrolled
BreastOther solid neoplasm

Advanced Solid Tumors With an Alteration of the PIK3CA Gene

NCT01449058 2017-10-02

A Phase Ib Study of MEK162 Plus BYL719 in Adult Patients With Selected Advanced Solid Tumors

Array BioPharma

Phase 1 Completed
139 enrolled
Other solid neoplasm

Advanced and Selected Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡